Skip to main content
Fig. 3 | Stem Cell Research & Therapy

Fig. 3

From: Human placenta-derived mesenchymal stem cells transplantation in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 (phase I clinical trial): safety profile assessment

Fig. 3

The changes in the vital signs 24 h after PL-MSC transplantation and comparison to the control group. Body temperature (A), heart rate (B), systolic blood pressure (C), and O2 saturation (E) were increased after PL-MSC transplantation but the diastolic blood pressure (D) was decreased compared to the control group. None of these differences were statistically significant

Back to article page